The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure

Beşli, Feyzullah; Güllülü, Sümeyye; Sağ, Saim; Keçebaş, Mesut; Acikgoz, Ebru; Sarandöl, Emre; Aydınlar, Ali

doi:10.1080/ac.71.2.3141848

Cited by 5 publications

(3 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, higher PTX-3 levels were associated with the severity and prognosis of HF (22). sLOX-1 levels were elevated in patients with HF and negatively correlated with systolic cardiac function (23). Furthermore, PTX-3 levels are positively correlated with the severity of PAD (24), and sLOX-1 levels are inversely correlated with the anklebrachial index in patients with type 2 diabetes mellitus (25).…”

Section: Figure 1 Kaplan-meier Curve For Cardiovascular Events In Pat...mentioning

confidence: 99%

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients

OSAWA,

NAKAMURA,

TSUTAYA

et al. 2024

In Vivo

View full text Add to dashboard Cite

Background/Aim: The pathogenesis of cardiovascular disease (CVD) in hemodialysis (HD) patients involves inflammation and oxidative stress. High-sensitivity C-reactive protein (hs-CRP) is an established inflammatory biomarker associated with CVD. Several studies have suggested that the inflammatory biomarker pentraxin-3 (PTX-3) and the oxidative stress-related biomarker soluble lectinlike low-density lipoprotein receptor-1 (sLOX-1) are novel biomarkers for CVD in non-HD populations. This study aimed to clarify the association of these established and novel biomarkers with future cardiovascular (CV) events in HD patients. Patients and Methods: This was a single-center prospective cohort study that included 255 HD patients. The primary outcome was the composite of nonfatal and fatal CV events. The event-free survival rate between the two groups according to the median plasma level of each biomarker at baseline was evaluated using the Kaplan-Meier method. The risk for CV events at elevated levels of each biomarker was estimated using Cox proportional hazard model. Results: We observed 44 CV events during the median follow-up period of 743 days. The event-free survival rate significantly differed between the two groups in hs-CRP but not in PTX-3 or sLOX-1. The unadjusted hazard ratio (HR) for CV events in patients with hs-CRP levels above the median was 2.63 [95% confidence interval (CI)=1.37-5.02]. The HR remained significant after adjusting for age, sex, history of CVD, and diabetes (HR=2.30;. Conclusion: In HD patients, hs-CRP may have a predictable role for future CV events, whereas PTX-3 and sLOX-1 do not.Patients on hemodialysis (HD) have a high risk for morbidity and mortality due to cardiovascular disease (CVD) (1). Biomarkers that may predict future cardiovascular (CV) events may allow for the early recognition of high-risk patients and increase opportunities for appropriate therapy, improving their prognosis. Inflammation and oxidative stress are involved in the pathophysiology of CVD in patients on HD (2). Thus, biomarkers that reflect inflammation and oxidative stress may serve as predictors of future CV events in patients on HD.High-sensitivity C-reactive protein (hs-CRP) is an established inflammatory biomarker, with elevated levels predicting CV events in the general population (3, 4). Although increased levels of hs-CRP are associated with allcause or CV mortality in patients on HD (5, 6), its relationship with future CV events remains unknown. Pentraxin-3 (PTX-3) is an acute phase reactant belonging to the PTX superfamily, in which CRP belongs to, but its cellular source and regulation of production are different from those of CRP (7). PTX-3 may be closely associated with 1351

show abstract

Section: Figure 1 Kaplan-meier Curve For Cardiovascular Events In Pat...mentioning

confidence: 99%

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients

OSAWA,

NAKAMURA,

TSUTAYA

et al. 2024

In Vivo

View full text Add to dashboard Cite

show abstract

“…To evaluate sLOX-1 as a biomarker for systolic heart failure, serum sLOX-1 levels were measured in 55 patients with systolic heart failure and compared to a control group of 25 individuals. Serum sLOX-1 levels were found to negatively correlate with left ventricular ejection fraction, particularly in patients with ischemia-related aetiology [ 84 ]. The relationship between LOX-1 and C-reactive protein (CRP) in atherogenesis and their role as biomarkers for cardiovascular events is an area of ongoing interest.…”

Section: Srs As Biomarkers In Cvdmentioning

confidence: 99%

Scavenger Receptors as Biomarkers and Therapeutic Targets in Cardiovascular Disease

Cuthbert

Shaik

Harrison

et al. 2020

Cells

View full text Add to dashboard Cite

The process of atherosclerosis leads to the formation of plaques in the arterial wall, resulting in a decreased blood supply to tissues and organs and its sequelae: morbidity and mortality. A class of membrane-bound proteins termed scavenger receptors (SRs) are closely linked to the initiation and progression of atherosclerosis. Increasing interest in understanding SR structure and function has led to the idea that these proteins could provide new routes for cardiovascular disease diagnosis, management, and treatment. In this review, we consider the main classes of SRs that are implicated in arterial disease. We consider how our understanding of SR-mediated recognition of diverse ligands, including modified lipid particles, lipids, and carbohydrates, has enabled us to better target SR-linked functionality in disease. We also link clinical studies on vascular disease to our current understanding of SR biology and highlight potential areas that are relevant to cardiovascular disease management and therapy.

show abstract

“…Recently, inflammatory HDL from SLE patients was shown to reduce the nuclear co-localization of ATF3, an anti-inflammatory transcription factor, through the LOX-1 receptor, making primary human monocyte-derived macrophages prone to inflammatory cytokine secretion [24]. In human disease, elevated levels of cleaved soluble LOX-1 (sLOX-1) have been reported in patients with acute coronary syndrome [25,26], systolic heart failure [27], ischemic stroke [28], and psoriasis [29].…”

Section: Introductionmentioning

confidence: 99%

LOX-1: A potential driver of cardiovascular risk in SLE patients

et al. 2020

View full text Add to dashboard Cite

Traditional cardiovascular disease (CVD) risk factors, such as hypertension, dyslipidemia and diabetes do not explain the increased CVD burden in systemic lupus erythematosus (SLE). The oxidized-LDL receptor, LOX-1, is an inflammation-induced receptor implicated in atherosclerotic plaque formation in acute coronary syndrome, and here we evaluated its role in SLE-associated CVD. SLE patients have increased sLOX-1 levels which were associated with elevated proinflammatory HDL, oxLDL and hsCRP. Interestingly, increased sLOX-1 levels were associated with patients with early disease onset, low disease activity, increased IL-8, and normal complement and hematological measures. LOX-1 was increased on patient-derived monocytes and low-density granulocytes, and activation with oxLDL and immune-complexes increased membrane LOX-1, TACE activity, sLOX-1 release, proinflammatory cytokine production by monocytes, and triggered the formation of neutrophil extracellular traps which can promote vascular injury. In conclusion, perturbations in the lipid content in SLE patients' blood activate LOX-1 and promote inflammatory responses. Increased sLOX-1 levels may be an indicator of high CVD risk, and blockade of LOX-1 may provide a therapeutic opportunity for ameliorating atherosclerosis in SLE patients.

show abstract

The relationship between serum lectin-like oxidized LDL receptor-1 levels and systolic heart failure

Abstract: Our study demonstrates the utility of the serum LOX-1 levels in the diagnosis of left ventricular systolic heart failure. LOX-1 may have a place in the diagnosis of heart failure, in particular in patients with ischaemic cardiomyopathy.

Cited by 5 publications

References 10 publications

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients

Role of High-sensitivity C-reactive Protein in Future Cardiovascular Events in Hemodialysis Patients

Scavenger Receptors as Biomarkers and Therapeutic Targets in Cardiovascular Disease

LOX-1: A potential driver of cardiovascular risk in SLE patients

Contact Info

Product

Resources

About